Responses

PDF
Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Step up therapy remains an appropriate option

    Dear Editor,

    I congratulate the research team from Rotterdam for the high quality study design of the tREACH study, but their conclusions are over-stated [1]. Their quotation of the literature is incomplete, referring to studies that have studied initial combination DMARDs plus corticosteroid (BeSt, FinRACo, COBRA) but excluding those studies that do not support their conclusions. There have been two previously publ...

    Show More
    Conflict of Interest:
    None declared.